主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PALI
#4213
Palisade Bio, Inc. Common Stock
1.940
0
USD
-4.43%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
-4.43%
每月变动
+14.12%
6个月变化
+14.12%
年变化
+14.12%
前一天收盘价
2.030
0
Open
1.940
0
Bid
1.940
0
Ask
1.943
0
Low
1.940
0
High
1.940
0
交易量
48
市场
股票
医疗保健
PALI
Open full chart
Financials
Overview
声明
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
23.06 K
24.31 K
300.27 K
851.4 K
4.4 M
—
Valuation ratios
Enterprise value
—
—
—
—
-2.56 M
117.13 M
Price to earnings ratio
—
—
—
—
-0.16
-1.2
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
0.19
0.72
Price to book ratio
—
—
—
—
0.31
0.52
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
1.25
2.13
0.9
0.88
1.33
1.41
Return on equity %
1.67
3.61
1.14
1.09
1.93
2.82
Return on invested capital %
2 774.57
17.62 K
4 918.58
2 935.43
3 887.25
—
Gross margin %
100
100
—
100
—
—
Operating margin %
78.96 K
15 K
—
5 228
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
120.32 K
9 539.78
—
4 920
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
4.02
4.96
4.89
5.15
3.24
9.67
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.02
0
0.02
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0
-0.01
-0.01
-0.01
-0.15
Long term debt to total equity ratio
—
0
-0.01
-0.01
-0.01
-0.33
Per share metrics
Operating cash flow per share
—
1 185.26
227.65
24.41
8.61
3.17
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
842.43
211.29
27.19
6.92
10.46
Net current asset value per share
—
992.79
251.04
29.23
7.41
11.59
Tangible book value per share
—
590.74
212.6
24.8
5.29
7.51
Working capital per share
—
792.53
199.72
23.56
5.12
7.29
Book value per share
—
590.74
212.6
24.8
5.29
7.51
新闻
Stifel首次覆盖Palisade Bio股票,基于IBD药物给予买入评级
Stifel initiates Palisade Bio stock with buy rating on IBD drug
Palisade Bio在ECCO大会上展示溃疡性结肠炎药物试验数据
Palisade Bio presents ulcerative colitis drug trial data at ECCO
Palisade Bio appoints IBD expert to clinical advisory board
Palisade Bio (PALI) 首席医疗官Jones出售价值$3480的股票
Palisade Bio首席执行官Finley出售价值$6818的股份
Palisade Bio任命两位IBD专家加入临床顾问委员会
Palisade Bio appoints two IBD experts to clinical advisory board
Palisade Bio董事Williams以每股1.88美元购入价值9,400美元股票
Palisade Bio director Williams buys $9,400 in shares
B.Riley 以买入评级开始对 Palisade Bio 股票进行覆盖